Across TCGA pan-cancer cohorts, FAM221A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM221A data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher FAM221A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FAM221A expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

GBM, LUAD, and HNSC are the cancer types where FAM221A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.365	0.654	.010	18	view →
LUAD	DFS	Quartile	All	0.553	0.884	.026	12	view →
HNSC	DFS	Median	II,III,IV	1.000	0.902	.024	4	view →
PDAC	DFS	Median	II,III,IV	0.502	0.301	.020	2	view →
LSCC	DFS	Median	All	0.902	0.974	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: FAM221A tumor-vs-normal RNA expression · all FAM221A data types